

Liquent

# Information Technology Strategic Planning; Public Meeting

October 19, 2008

Jim Nichols, Vice President of Product Strategy

# Caveats

- Focused on questions asked that impact areas where Lipient interacts with stakeholders

# What would help improve the quality of electronic submissions to the agency?

- Areas where FDA has influence on quality
  - Standards definition
  - Consistency of standards within FDA
  - Communication with stakeholders
  
- Standards Definition
  - Global standards desired
  - Submission validation criteria
  - SPL
    - Clarification on FDA's thoughts on PLR and MedDRA and SNOMED coding
    - Improved feedback mechanism communicating non-critical technical issues and formal process for correcting

# What would help improve the quality of electronic submissions to the agency? continued

- Consistency of standards within FDA
  - Standard rules for electronic submissions across FDA centers
  - Incorporation of DDMAC and APLS submissions into eCTD submissions
  - Increased communication between Reviewers and Office of Business Process
    - Provide instructions on how to handle requests for information outside of typical eCTD specification
      - Example: Received requests for dataset programs

# What would help improve the quality of electronic submissions to the agency? continued

## ➤ Communication with stakeholders

- Guidance clarification
  - Study Tagging Files
  - Cross application references
  - Hyperlinking
  - INDs in eCTD format
- Lessons learned from submissions received
- Understanding of validation criteria
- Expectations regarding documentation
  - Inter and intra-document links (including lifecycle)
  - Document level tables of contents
- LCM operator usage
- Reviewer training

# What would help increase the quantity of electronic submissions to the agency?

- Provide temporary incentives for electronic submissions
  - Reduced fees
  - Faster action dates
- Increase acceptance with FDA
  - DDMAC and APLS submissions
    - Provide graphical representation with request option for physical sample?
    - Provide text portions as separate PDF for easier review?

# How would you prioritize these quality and quantity improvements?

Improvement Area	Priority
Standards Definition	3
Consistency of standards within FDA	1
Communication with stakeholders	2
Provide temporary incentives for electronic submissions	5
Increase acceptance with FDA	4

# What data standards are needed to implement these improvements?

- Standard for exchange of promotional materials
- Communication Exchange
- SDTM and SEND implementation
- Considerations for XML document exchange
  - Protocol
  - Case Report Forms
  - Stability
  - Others?



# How should FDA engage stakeholders while developing, testing, and implementing these solutions?

- Public Meetings
- Ability to comment
- Workgroup/Testing Teams
- Post Mortem Teams for ongoing improvement

# What lead time is needed for stakeholders to respond to and be in alignment with FDA initiatives?

## ➤ Depends on complexity of change

### – Minor

- Example: change to allowable values for STF attributes, additions to dictionary lists for SPL, electronic signature
- 3 – 9 months from final standard

### – Moderate

- Example: Structured Product Labeling, move to eCTD v3.3 specification
- 1 year from final standard

### – Major

- Example: move to Regulated Product Submission, CDISC standards
- 2 years from final standard

# What data standards areas provide the greatest challenge?

- Standards associated with unstructured content
  - Protocol Representation
  - Structured Product Labeling
  - Etc.
- Standards associated with content that will have a continual lifecycle over many years
- Most difficult for industry to implement and for the agency to manage

# What approaches will facilitate the most effective & efficient adoption & implementation of data standards?

- Early involvement from agency, industry and software vendors
- Global input early in standards development
- Commitment to harmonized standards
- Assignment of business process manager to sponsors to assist with questions on development and maintenance of eCTDs.

# What key areas require new or expanded electronic submissions guidance?

## ➤ eCTD

- Clarification on corresponding actions for appending leaf elements when parent leaf is deleted or replaced
- Recommendations for migrating to V3.3.3 of eCTD specification
- Clarification on STF files when a study is referenced in multiple sections of an application
- Clarification on how to perform cross-application references
- Clarification of INDs in eCTD format
- Clarification on LCM
- Clarification on EDC CRFs

## ➤ RPS

- Current agency thinking on usage and implementation

## ➤ CDRH? CVM?

# What lessons learned & best practices should FDA consider as we transition from program-specific to enterprise IT solutions using a reusable and modular model?

- Need to look for revision to EU telematics strategy to see if possible recommendations
- Other possibilities
  - Enterprise standards
  - Consistent processes across centers
  - Training
  - Scalable and open technology

# What specific concerns (i.e., security, confidentiality, etc.) exist for a third party entity or entities providing services related to electronic submissions and review and how can they be addressed?

- Not sure this is an issue. Would expect all 3rd parties used by FDA to have to abide by confidentiality agreements
- Security perhaps
  - Secure access and transfer of information
  - Ensuring 3rd party computers are secure